News

Company has received all of the regulatory approvals to begin its pivotal efficacy trial.

Collaboration to discover novel therapeutic antibodies targeting cancer.

Many patients in the latter stage of Parkinson's disease are at high risk of dangerous, sometimes fatal, falls. One major reason is the disabling symptom referred to as freezing of gait (FoG) — brief episodes of an inability to step forward that typically occurs during gait initiation or when turning while walking.

Working towards the ultimate goal to develop therapeutics to treat diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), and bovine spongiform encephalopathy (BSE or mad cow disease), University of Alberta scientists Michael Woodside, Hao Yu, and Derek Dee are investigating the physical principles underlying the formation of misfolded protein aggregates.

Study shows injectable drug given every two weeks works better than daily pill for those who have been recently diagnosed.

Regions of bird's brain likely duplicated at least 29 million years ago.

The clinical informatics company partners with NHS, University of Glasgow and Philips Healthcare on unique brain injury study.

Both companies explore how to break down major technical barriers that increasingly hinder biomedical research.

Study identifies small-molecule compound that protects cells against ER stress.

A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.